Literature DB >> 12099647

The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours.

A R Carmichael1, S Bendall, L Lockerbie, R Prescott, T Bates.   

Abstract

AIM: There is uncertainty in the literature as to whether bilateral breast cancer carries a worse prognosis than unilateral disease because some studies suggest that the development of a second primary does not influence survival, while others report a decreased survival in patients suffering from bilateral disease.
METHODS: A prospectively accrued and regularly validated database of 1945 patients with breast cancer treated in a district general hospital between 1963 and 1999 was analysed for clinical and pathological tumour characteristics including family history, grade, type of tumour, treatment and outcome.
RESULTS: Five per cent of patients (92) suffered from metachronous and 43 (2%) from synchronous bilateral breast cancer. A family history of breast cancer was more common in patients with metachronous bilateral breast cancer (38%), compared with the unilateral group (15%) and the synchronous bilateral breast cancer group (17%) (chi(2)=22.9, P<0.001). Patients with synchronous bilateral breast cancer had a significantly worse overall survival when compared with those with metachronous bilateral or unilateral breast cancer (log-rank test chi(2)=6.1, P=0.047).
CONCLUSION: Women with metachronous breast cancer were more likely to have positive family history, while those with synchronous bilateral breast cancer tend to have shorter survival when compared with those with unilateral breast cancer. Synchronous bilaterality is not, however, an independent risk factor on multivariate analysis. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12099647     DOI: 10.1053/ejso.2002.1266

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  26 in total

1.  Dosimetric advantages of generalised equivalent uniform dose-based optimisation on dose-volume objectives in intensity-modulated radiotherapy planning for bilateral breast cancer.

Authors:  T-F Lee; H-M Ting; P-J Chao; H-Y Wang; C-S Shieh; M-F Horng; J-M Wu; S-A Yeh; M-Y Cho; E-Y Huang; Y-J Huang; H-C Chen; F-M Fang
Journal:  Br J Radiol       Date:  2012-11       Impact factor: 3.039

2.  The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients.

Authors:  Xinrui Liang; Danhua Li; Wenwen Geng; Xuchen Cao; Chunhua Xiao
Journal:  Tumour Biol       Date:  2013-01-09

3.  Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice.

Authors:  Moshe Elkabets; Ann M Gifford; Christina Scheel; Bjorn Nilsson; Ferenc Reinhardt; Mark-Anthony Bray; Anne E Carpenter; Karin Jirström; Kristina Magnusson; Benjamin L Ebert; Fredrik Pontén; Robert A Weinberg; Sandra S McAllister
Journal:  J Clin Invest       Date:  2011-01-25       Impact factor: 14.808

4.  Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience.

Authors:  Robert Díaz; Blanca Munárriz; Ana Santaballa; Laura Palomar; Joaquín Montalar
Journal:  Med Oncol       Date:  2010-12-31       Impact factor: 3.064

5.  Bilateral breast cancer following augmentation mammaplasty with polyacrylamide hydrogel injection: A case report.

Authors:  Yaning Zhao; N A Yuan; Kuanzhi Li; Y I Geng; Haiping Zhou; Hua Wang; Jie Hou; Bin Zhang; Yuan Cai; Xinhan Zhao
Journal:  Oncol Lett       Date:  2015-04-14       Impact factor: 2.967

6.  Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer.

Authors:  Yan-Xia Shi; Qing Xia; Rou-Jun Peng; Zhong-Yu Yuan; Shu-Sen Wang; Xin An; Ye Cao; Yu-Ting Tan; Ying Jin; Xiu-Yu Cai; Yue-Li Sun; Xiao-Yu Teng; Dong-Geng Liu; Wen-Qi Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-12       Impact factor: 4.553

7.  Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost.

Authors:  Alba Fiorentino; Rosario Mazzola; Stefania Naccarato; Niccolò Giaj-Levra; Sergio Fersino; Gianluisa Sicignano; Umberto Tebano; Francesco Ricchetti; Ruggero Ruggieri; Filippo Alongi
Journal:  Radiol Med       Date:  2017-02-21       Impact factor: 3.469

8.  Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.

Authors:  Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

9.  Histo-biological comparative analysis of bilateral breast cancer.

Authors:  Bilal Baker; Basem Morcos; Faiez Daoud; Maher Sughayer; Maher Sughayyer; Hisham Shabani; Habeeb Salameh; Mahmoud Almasri
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

10.  Breast-Conserving Surgery in Bilateral Breast Cancer.

Authors:  Julie A O'Brien; Alice Ho; G Paul Wright; Michelle Stempel; Sujata Patil; Kate Krause; Monica Morrow; Mary L Gemignani
Journal:  Ann Surg Oncol       Date:  2015-08-12       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.